200 related articles for article (PubMed ID: 25720573)
1. Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer.
Kos M; Hocazade C; Kos FT; Uncu D; Karakas E; Dogan M; Uncu HG; Yildirim N; Zengin N
Wien Klin Wochenschr; 2016 Sep; 128(17-18):635-40. PubMed ID: 25720573
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer.
Zhang H; Xia H; Zhang L; Zhang B; Yue D; Wang C
Am J Surg; 2015 Sep; 210(3):526-35. PubMed ID: 26105800
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer.
Kim SH; Lee HW; Go SI; Lee SI; Lee GW
Oncotarget; 2016 Jun; 7(24):36198-36206. PubMed ID: 27105529
[TBL] [Abstract][Full Text] [Related]
5. Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion.
Lim JU; Yeo CD; Kang HS; Park CK; Kim JS; Kim JW; Kim SJ; Lee SH
Sci Rep; 2019 Mar; 9(1):4721. PubMed ID: 30886226
[TBL] [Abstract][Full Text] [Related]
6. Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort.
Yuan C; Li N; Mao X; Liu Z; Ou W; Wang SY
Thorac Cancer; 2017 Jul; 8(4):350-358. PubMed ID: 28544400
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.
Cannon NA; Meyer J; Iyengar P; Ahn C; Westover KD; Choy H; Timmerman R
J Thorac Oncol; 2015 Feb; 10(2):280-5. PubMed ID: 25299234
[TBL] [Abstract][Full Text] [Related]
8. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
Yılmaz U; Ozdemir O; Batum O; Ermin S
Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
[TBL] [Abstract][Full Text] [Related]
9. The Prognostic Value of PLR in Lung Cancer, a Meta-analysis Based on Results from a Large Consecutive Cohort.
Ding N; Pang Z; Shen H; Ni Y; Du J; Liu Q
Sci Rep; 2016 Oct; 6():34823. PubMed ID: 27703265
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients.
Gu X; Sun S; Gao XS; Xiong W; Qin S; Qi X; Ma M; Li X; Zhou D; Wang W; Yu H
Sci Rep; 2016 Mar; 6():23893. PubMed ID: 27025911
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
Guo D; Li M; Chen D; Jing W; Zhu H; Fu L; Kong L; Yue J; Yu J
Future Oncol; 2019 Feb; 15(6):625-635. PubMed ID: 30430864
[TBL] [Abstract][Full Text] [Related]
12. Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non-small cell lung cancer undergoing stereotactic body radiotherapy.
Fang F; Jia Z; Xie H; Cao Y; Zhu X; Yang XY; Guo X; Zhang H
Clin Respir J; 2024 May; 18(5):e13749. PubMed ID: 38685745
[TBL] [Abstract][Full Text] [Related]
13. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
[TBL] [Abstract][Full Text] [Related]
14. Platelet-to-lymphocyte ratio predicts the prognosis of patients with non-small cell lung cancer treated with surgery and postoperative adjuvant chemotherapy.
Toda M; Tsukioka T; Izumi N; Komatsu H; Okada S; Hara K; Miyamoto H; Ito R; Shibata T; Nishiyama N
Thorac Cancer; 2018 Jan; 9(1):112-119. PubMed ID: 29105365
[TBL] [Abstract][Full Text] [Related]
15. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?
Unal D; Eroglu C; Kurtul N; Oguz A; Tasdemir A
Asian Pac J Cancer Prev; 2013; 14(9):5237-42. PubMed ID: 24175807
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: A meta-analysis including 3,720 patients.
Zhao QT; Yuan Z; Zhang H; Zhang XP; Wang HE; Wang ZK; Duan GC
Int J Cancer; 2016 Jul; 139(1):164-70. PubMed ID: 26915723
[TBL] [Abstract][Full Text] [Related]
17. Preoperative platelet to lymphocyte and neutrophil to lymphocyte ratios are independent prognostic factors for patients undergoing lung cancer radical surgery: A single institutional cohort study.
Lan H; Zhou L; Chi D; Zhou Q; Tang X; Zhu D; Yue J; Liu B
Oncotarget; 2017 May; 8(21):35301-35310. PubMed ID: 27845912
[TBL] [Abstract][Full Text] [Related]
18. Platelet-lymphocyte ratio is an independent prognostic factor in patients with ALK-positive non-small-cell lung cancer.
Han Y; Wang J; Hong L; Sun L; Zhuang H; Sun B; Wang H; Zhang X; Ren X
Future Oncol; 2017 Jan; 13(1):51-61. PubMed ID: 27523323
[TBL] [Abstract][Full Text] [Related]
19. Can we define any marker associated with brain failure in patients with locally advanced non-small cell lung cancer?
Sert F; Cosgun G; Yalman D; Ozkok S
Cancer Radiother; 2021 Jun; 25(4):316-322. PubMed ID: 33422415
[TBL] [Abstract][Full Text] [Related]
20. Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio in predicting survival for patients with stage I-II gastric cancer.
Sun X; Liu X; Liu J; Chen S; Xu D; Li W; Zhan Y; Li Y; Chen Y; Zhou Z
Chin J Cancer; 2016 Jun; 35(1):57. PubMed ID: 27342313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
